An Open-label, Multicenter, Expanded Access Study of Oral AMN107 in Adult Patients With Imatinib-resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase, or Chronic Phase.

Inclusion Criteria

Inclusion criteria:

- Imatinib-resistant or -intolerant Philadelphia chromosome-positive chronic myeloid
leukemia in blast crisis, accelerated phase, or chronic phase.

- Chronic myeloid leukemia patients who have been treated with an investigational
tyrosine kinase inhibitor.

- Laboratory values within normal limits.

Exclusion criteria:

- Impaired cardiac function.

- Acute or chronic liver or renal disease considered unrelated to tumor.

- Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled
diabetes, active or uncontrolled infection) that could cause unacceptable safety
risks or compromise compliance with the protocol.

- Patients who are currently receiving treatment with any of the medications that have
the potential to prolong the QT interval or to inhibit the metabolism of AMN107
(CYP3A4/5 inhibitors).

- Patients with a history of another malignancy that is currently clinically
significant or currently requires active intervention.

Other protocol-defined inclusion/exclusion criteria may apply.